Reports Q2 revenue $15.42B, consensus $15.03B. “AbbVie (ABBV) delivered another outstanding quarter with strong performance from our diversified growth platform. We also made meaningful pipeline progress with several regulatory approvals, encouraging clinical data and strategic investments in promising external innovation,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “We’re entering the second half of the year with substantial momentum and are once again raising our full-year outlook.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Options Volatility and Implied Earnings Moves Today, July 31, 2025
- M&A News: AbbVie Eyes $1B Acquisition of Gilgamesh Therapeutics
- Is ABBV Stock (ABBV) a Buy Ahead of Q2 Earnings?
- AbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports
- Notable companies reporting before tomorrow’s open